Table 2
Sensitivity, specificity, positive and negative predictive values of p53 immunohistochemistry (IHC) and assessment of dysplasia in the prognosis of potentially malignant oral lesions
| Marker | Sensitivity | Specificity | Positive predictive value (PPV) | Negative predictive value (NPV) |
|---|---|---|---|---|
| *All lesions entered for analysis, irrespective of presence of the marker at margins of the histological section; †lesions harbouring the marker were only entered for analysis when this extended at least into one margin of the histological section. | ||||
| Sensitivity: proportion of the “progressive lesions” (cases) that harbour the marker. Specificity: proportion of the “non-progressive lesions” (controls) that do not harbour the marker. PPV: proportion of the lesions harbouring the marker that progressed to carcinoma. NPV: proportion of the lesions not harbouring the marker that did not progress to carcinoma. | ||||
| Moderate or severe dysplasia* | 12/18 (67%) | 13/18 (72%) | 12/17 (71%) | 13/19 (68%) |
| Suprabasal p53 immunoexpression* | 6/18 (33%) | 15/18 (83%) | 6/9 (67%) | 15/27 (56%) |
| Moderate or severe dysplasia† | 10/16 (62.5%) | 13/15 (87%) | 11/13 (85%) | 13/19 (68%) |
| Suprabasal p53 immunoexpression† | 5/17 (29%) | 15/15 (100%) | 5/5 (100%) | 15/27 (56%) |
